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Summary
Biotechnology, with the main applications in food and nutrition, dates back to the early
times of mankind. In the recent decades the progress in natural sciences, mathematics and
computer science has led to a new branch termed molecular biotechnology, which finally
developed as an autonomous scientific discipline. The field of biotechnology, in the past
generally empirically driven, now largely benefits from molecular biotechnology by improved
systems, knowledge and understanding. Thereby, compliance with the recently published
initiatives of the regulatory authorities to accelerate the approval process for the manufac-
turing of biopharmaceuticals can be gained.
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Introduction
The benefit of biotechnology for the welfare of man-
kind has a long history. Biotechnology commonly defined
as the scientific application of microbiology and biochem-
istry in close connection with chemical, process and plant
engineering for the utilisation of biological phenomena
on technical and industrial scale has experienced a sub-
stantial change during the recent decades. For a long pe-
riod food technology was the main area of application.
Nowadays, biotechnology significantly contributes to the
areas of health, nutrition and environment. Due to the
high impact of biotechnology on the welfare and the
economy of human society, biotechnology and health are
even regarded as the bearers of the 6th Kondratieff cy-
cle, thus representing a landmark of scientific and eco-
nomic development (1–4).
In the context of the special edition of the journal it
is important to note that the work life of Prof. Mildner
largely corresponds with the remarkable development of
biotechnology.
Evolution of Biotechnology
As mentioned, in the past the main area of biotech-
nology was food technology. Due to the impact of nutri-
tion on health in former times, biotechnology was close-
ly associated with traditional medicine. However, the
less explored knowledge of nutritional science often re-
sulted in hazardous adverse reactions or even disease
caused by effects of food. In the last century the arti-
sanal craft processes of food technology were more and
more mechanised, which was the beginning of industrial
food production. In parallel, at the end of the 19th cen-
tury, organic chemistry gained ground in the synthesis
of pharmaceuticals over compounds extracted from nat-
ural resources. Among others, the well known acetylsali-
cylic acid (ASA) or the sulphonamides are typical exam-
ples. However, the discovery of penicillin by Fleming in
1928 brought a paradigm change in the application of
pure chemical drugs to biopharmaceuticals. The follow-
ing efforts to develop production of penicillin and other
antibiotics on industrial scale can be seen as a corner-
stone in pharmaceutical biotechnology-based manufac-
turing (for details refer to Buchholz and Collins (5), and
Hulse (6)). The specific requirements of penicillin pro-
duction connected with pure cultures on a large scale in-
troduced the application of engineering principles and
skills. As an example, in the beginning Penicillium sp.
was cultivated in milk bottles prior to the construction
of bioreactors. Process development and construction of
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plants on industrial scale was strongly forced by the
high requirement of antibiotics due to the Second World
War. Interestingly, Prof. Mildner graduated in organic
chemistry during that time and also got involved in a
pharmaceutical company.
In the context of biotechnology as the carrier of the
6th Kondratieff cycle, it is worth mentioning that a fun-
damental attribute of such long-term cycles is the con-
vergence of a series of mutually complementing techni-
cal and methodological innovations leading to complex
systems. The key disciplines of modern biotechnology
are biological sciences, (bio)chemistry, informatics, math-
ematics, and engineering science. Each of these showed
significant progress in the recent decades. In brief, bio-
logical sciences have been strongly stimulated by molec-
ular biology, in particular by the discovery of the struc-
ture of DNA, gene cloning and the significant progress
in bio-analytics such as genome sequencing and develop-
ment of high throughput -omics platforms. The advances
in molecular biology have been greatly supported by
the rapidly growing capabilities of computer science (7).
To cope with the wealth of data, bioinformatics adopted
a series of methods to store, retrieve, organize and ana-
lyze biological data. The availability of such comprehen-
sive data sets has led to a change from 'hypothesis
driven' to 'data driven' investigations using statistical
modelling. Moreover, the comprehensive and partly
quantitative data sets provide the basis for mathematical
modelling and simulation of pathways and regulatory
networks. The progress in computer science also pro-
vided the basis for advanced process control and auto-
mation. At this point it needs to be said that the current
high level of biotechnology is to a major part the result
of inter- and transdisciplinary collaboration of many
open-minded scientists from the different fields. It needs
to be emphasized that often work had to be performed
under stringent economic conditions. At this point the
value of Prof. Mildner's contribution to research and edu-
cation also has to be honoured.
Following the progress in science within the recent
years, biotechnology has undergone a change. In addi-
tion to the traditionally defined utilisation of biological
phenomena for the production of goods on technical
scale, recently the field has been extended to 'molecular
biotechnology'. In brief, molecular biotechnology encom-
passes a broad spectrum of laboratory techniques such
as molecular biology, biochemistry, microbiology, immu-
nology and cell biology applied for targeted modifica-
tion of cellular systems in the production of therapeutic
molecules and/or biocatalysts used in the area of white
biotechnology. Currently the major part of products is
applied in the health area. In addition to the biosynthe-
sis of specific molecules, the use of modified cells in
cell-based therapies is an increasing field of application
in personalised medicine. A strong impetus to molecular
biotechnology in direction of health applications was
triggered by the human genome project (HUGO), which
started around 1990. In parallel, in the wake of the hu-
man genome project, the capabilities and the perfor-
mance of the analytical equipment advanced signifi-
cantly. The knowledge of the human genome offers new
possibilities in diagnosis and therapy. Moreover, it opens
new insights into the complexity of cellular systems for
targeted treatment of diseases. Interestingly, based on
the improved understanding of cellular regulatory net-
works, recently medicinal chemistry approaches have
been investigated more extensively as new drugs lead to
targeted interaction with specific pathological entities.
Such therapeutic concepts might result in a substantial
reduction of costs of goods (COGs).
As a whole, molecular biotechnology encompassing
biochemistry, molecular biology and cell biology, bioin-
formatics and mathematical modelling has evolved into
a new scientific discipline in the framework of life sci-
ences (5).
Impact of Molecular Biotechnology on the
Production of Biopharmaceuticals
The observability and controllability of biopharma-
ceutical production processes is generally impaired by
the complexity of the cell factory and the insufficient in-
sight into the synthesis processes. Therefore, in the past,
and due to the usually long life cycle of biopharmaceu-
tical production processes as a consequence of stringent
regulatory and intellectual property issues even in pres-
ent times, the upstream processes are run under a tight
control regime of a few state parameters. The required
product quality and efficacy are assured by in-depth ana-
lysis of the product afterwards. Such an approach 'qual-
ity by quality control' does not comply with modern
process control strategies which are based on timely mea-
surements and interventions in the course of the produc-
tion process. Based on the advances in modern biotech-
nology offering better insight into the cell factories and
improved process understanding, the regulatory author-
ities started an initiative to transform and facilitate the
acceleration of the marketing authorisation approval pro-
cess of biopharmaceuticals. The key requirements are to
improve process knowledge and understanding to lower
the risk of application of the specific drug. The key ele-
ments of this initiative are Process Analytical Technol-
ogy (PAT), Quality by Design (QbD) and the definition
of the Design Space (8). PAT is focused on advanced
timely monitoring, the QbD concept aims at understand-
ing of the production process in accordance with the
knowledge of the risks involved in manufacturing. The
Design Space defines valid operation parameters to meet
the product quality attributes within a solution space.
Detailed definitions are documented in the guidelines is-
sued in the recent years by International Conference on
Harmonisation (ICH): 'Pharmaceutical Development Q8
(R2)' (9), 'Quality Risk Management (ICH Q9)' (10), 'Phar-
maceutical Quality System (PQS) (ICH Q10)' (11) and
'ICH guideline Q11 on development and manufacture of
drug substances (chemical entities and biotechnological/
biological entities)' (12). The guidelines strongly empha-
size the benefits of increased understanding and knowl-
edge of the manufacturing process to lower the risks
and facilitate the approval process. In addition, the sup-
ported risk-based regulatory decisions are the basis for
improvements of the manufacturing process within the
approved design space. Hence, the envisaged reduction
of post-approval submissions and real-time quality con-
trol will result in reduced end-product release testing
and will shorten the time to the market as well.
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However, thus required increase of process knowl-
edge is impaired by the low observability of cellular
processes in real time due to (i) the lack of sensors re-
flecting the physiological state of the culture, (ii) the
complexity of the biochemical reactions involved in the
biosynthesis processes, and (iii) the constraints in obtain-
ing any signal from inside the cell. In the recent years,
progress in the following areas has enabled substantial
improvement of bioprocess monitoring capabilities: a)
biochemical/molecular biology-based off-line analytics
is subject to a dramatic improvement, e.g. –omic technol-
ogies, mass spectrometry, sequencing, etc.; b) new on-line
analytical devices exploiting chemophysical features ap-
peared on the market, e.g. dielectric spectroscopy for the
determination of biomass, multiwave 2D fluorescence to
acquire in situ emission, and acquisition of volatile or-
ganic compounds in the bioreactor exhaust gas by pro-
ton transfer reaction mass spectrometry (13,14); c) data
mining and data compression using computer-based sta-
tistical methods to extract key process variables (15);
and d) statistical modelling to predict process variables
that are not directly measurable in the required time
frame by generating correlations between on- and off-
-line data sets (16).
Hence, the application of a comprehensive monitor-
ing platform provides a readout of physiologically sig-
nificant variables such as active biomass and/or product
concentration in real time, which in turn can act as new
set points for advanced process control regimes.
To sum it up, molecular biotechnology played and
still plays a pivotal role in the fruitful development of
biomedical research and therapy and has also led to a
paradigm change in biopharmaceutical manufacturing.
Conclusion
The progress in natural sciences, mathematics and
computer science was heavily instrumental in the trans-
formation of biotechnology to an autonomous scientific
discipline – molecular biotechnology – which nowadays
exists in parallel to the traditional technology-driven bio-
technology. Remarkably, traditional biotechnology also
takes advantage from the progress in mathematics, sta-
tistics and specific areas of natural sciences to improve
process knowledge and understanding. Thereby, the in-
teraction of biotechnology and molecular biotechnology
largely contributes to the efficient and economic manu-
facturing of biologics. Analogous approaches have al-
ready been implemented and will be further applied in
food technology.
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